CR9609A - Formulaciones de una sal de bupropion de liberacion modificada - Google Patents

Formulaciones de una sal de bupropion de liberacion modificada

Info

Publication number
CR9609A
CR9609A CR9609A CR9609A CR9609A CR 9609 A CR9609 A CR 9609A CR 9609 A CR9609 A CR 9609A CR 9609 A CR9609 A CR 9609A CR 9609 A CR9609 A CR 9609A
Authority
CR
Costa Rica
Prior art keywords
formulations
bupropion salt
liberation
modified
modified liberation
Prior art date
Application number
CR9609A
Other languages
English (en)
Inventor
Werner Oberegger
Fang Zhou
Stefano Turchetta
Graham Jackson
Paul Maes
Pietro Massardo
Mohammad Ashty Saleh
Original Assignee
Biovail Lab Int Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37595948&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR9609(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biovail Lab Int Srl filed Critical Biovail Lab Int Srl
Publication of CR9609A publication Critical patent/CR9609A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/02—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C225/14—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being unsaturated
    • C07C225/16—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Nutrition Science (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion se relaciona con las formas farmaceuticas que comprenden una cantidad eficaz de una sal farmaceuticamente aceptable de brupropion (bromhidrato de brupropion) que es mas estable que el clorhidrato de bupropion.
CR9609A 2005-06-27 2007-12-19 Formulaciones de una sal de bupropion de liberacion modificada CR9609A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69390605P 2005-06-27 2005-06-27

Publications (1)

Publication Number Publication Date
CR9609A true CR9609A (es) 2008-11-24

Family

ID=37595948

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9609A CR9609A (es) 2005-06-27 2007-12-19 Formulaciones de una sal de bupropion de liberacion modificada

Country Status (14)

Country Link
US (15) US7884136B2 (es)
EP (3) EP2502621A1 (es)
JP (1) JP5095615B2 (es)
KR (1) KR101306635B1 (es)
CN (1) CN101534808A (es)
AU (1) AU2006261788B2 (es)
CA (1) CA2578626C (es)
CR (1) CR9609A (es)
EC (1) ECSP077999A (es)
IL (2) IL185760A (es)
NZ (1) NZ561375A (es)
RU (1) RU2408368C2 (es)
WO (1) WO2007002597A2 (es)
ZA (1) ZA200711123B (es)

Families Citing this family (242)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110033542A1 (en) 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
US11207805B2 (en) 2001-10-12 2021-12-28 Aquestive Therapeutics, Inc. Process for manufacturing a resulting pharmaceutical film
US8900498B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
US8603514B2 (en) 2002-04-11 2013-12-10 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US20190328679A1 (en) 2001-10-12 2019-10-31 Aquestive Therapeutics, Inc. Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US8900497B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for making a film having a substantially uniform distribution of components
US20070281003A1 (en) 2001-10-12 2007-12-06 Fuisz Richard C Polymer-Based Films and Drug Delivery Systems Made Therefrom
US8765167B2 (en) 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US10285910B2 (en) 2001-10-12 2019-05-14 Aquestive Therapeutics, Inc. Sublingual and buccal film compositions
US7357891B2 (en) 2001-10-12 2008-04-15 Monosol Rx, Llc Process for making an ingestible film
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
PT1476138E (pt) * 2002-02-21 2012-02-14 Valeant Internat Barbados Srl Formulações de libertação modificada de pelo menos uma forma de tramadol
US8323692B2 (en) * 2002-02-21 2012-12-04 Valeant International Bermuda Controlled release dosage forms
NZ527142A (en) 2003-07-23 2006-03-31 Douglas Pharmaceuticals Ltd A stable suspension formulation
ES2289650T3 (es) * 2004-03-03 2008-02-01 Chemi S.P.A. Sal monosodica del acido 3-piridil-1-hidroxietiliden-1,1-bifosfonico amorfa y procedimiento para la preparacion de la misma.
RU2408368C2 (ru) * 2005-06-27 2011-01-10 Биовэйл Лэборэториз Интернэшнл С.Р.Л. Препараты соли бупропиона с модифицированным высвобождением
US7645802B2 (en) * 2005-06-27 2010-01-12 Biovail Laboratories International Srl. Bupropion hydrobromide and therapeutic applications
US7671094B2 (en) * 2005-06-27 2010-03-02 Biovail Laboratories International S.R.L. Bupropion hydrobromide and therapeutic applications
US20070020228A1 (en) * 2005-07-22 2007-01-25 Williams Terry N Method of using a biosealant device
ES2646326T3 (es) 2005-08-03 2017-12-13 Sprout Pharmaceuticals, Inc. Uso de flibanserina en el tratamiento de la obesidad
WO2007035816A2 (en) * 2005-09-20 2007-03-29 Dr. Reddy's Laboratories Ltd. Paroxetine compositions
US8298601B2 (en) * 2005-10-11 2012-10-30 Purecircle Sdn Bhd Process for manufacturing a sweetener and use thereof
US9101160B2 (en) 2005-11-23 2015-08-11 The Coca-Cola Company Condiments with high-potency sweetener
US20070142804A1 (en) * 2005-12-16 2007-06-21 Bernard Bobby L Hollow-core fibers
US20070212414A1 (en) * 2006-03-08 2007-09-13 Penwest Pharmaceuticals Co. Ethanol-resistant sustained release formulations
GB0607534D0 (en) 2006-04-13 2006-05-24 Univ London Pharmacy Colonic drug delivery formulation
TW200806282A (en) * 2006-05-05 2008-02-01 Wyeth Corp Solid dosage formulations
WO2008000760A1 (en) 2006-06-30 2008-01-03 Boehringer Ingelheim International Gmbh Flibanserin for the treatment of urinary incontinence and related diseases
SG174026A1 (en) 2006-08-03 2011-09-29 Nitec Pharma Ag Delayed-release glucocorticoid treatment of rheumatoid disease
BRPI0715959A2 (pt) * 2006-08-21 2013-07-30 Jubilant Organosys Ltd composiÇço farmacÊutica de liberaÇço modificada de cloridrato de bupropion
US7964182B2 (en) * 2006-09-01 2011-06-21 USV, Ltd Pharmaceutical compositions comprising phosphate-binding polymer
WO2008062437A2 (en) * 2006-09-01 2008-05-29 Usv Limited Process for the preparation of sevelamer hydrochloride and formulation thereof
US8017168B2 (en) 2006-11-02 2011-09-13 The Coca-Cola Company High-potency sweetener composition with rubisco protein, rubiscolin, rubiscolin derivatives, ace inhibitory peptides, and combinations thereof, and compositions sweetened therewith
US20090088404A1 (en) * 2007-01-31 2009-04-02 Methylation Sciences International Srl Extended Release Pharmaceutical Formulations of S-Adenosylmethionine
US8821899B2 (en) * 2007-03-12 2014-09-02 Board Of Regents, The University Of Texas System Method and process for the production of multi-coated recognitive and releasing systems
WO2008112826A1 (en) * 2007-03-12 2008-09-18 Board Of Regents, The University Of Texas System Method and process for the production of multi-coated recognitive and releasing systems
US8771713B2 (en) * 2007-03-12 2014-07-08 Board Of Regents, The University Of Texas System Method and process for the production of multi-coated recognitive and releasing systems
US8741316B2 (en) * 2007-03-12 2014-06-03 Board Of Regents, The University Of Texas System Highly porous, recognitive polymer systems
US20080292683A1 (en) * 2007-05-24 2008-11-27 Monosolrx, Llc. Film shreds and delivery system incorporating same
WO2009050726A2 (en) * 2007-05-28 2009-04-23 Panacea Biotec Limited Compositions and methods for improved delivery of bupropion
US8349033B2 (en) * 2007-05-31 2013-01-08 The Penray Companies, Inc. Diesel fuel, diesel fuel additive, and associated method for using the same
US20090004281A1 (en) * 2007-06-26 2009-01-01 Biovail Laboratories International S.R.L. Multiparticulate osmotic delivery system
US20100203128A1 (en) * 2007-08-07 2010-08-12 Biovail Laboratories International Srl Bupropion hydrobromide and therapeutic applications
CL2008002693A1 (es) 2007-09-12 2009-10-16 Boehringer Ingelheim Int Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad
US20090074944A1 (en) * 2007-09-18 2009-03-19 Viva Pharmaceuticals Inc. Enteric coatings for orally ingestible compositions
US20090136650A1 (en) * 2007-09-18 2009-05-28 Viva Pharmaceuticals Inc. Enteric coatings for orally ingestible compositions
US20090155354A1 (en) * 2007-12-14 2009-06-18 Mclean Barbara Wanamaker Dispensing encapsulated liquids into body cavities
US20100291225A1 (en) * 2008-01-14 2010-11-18 Jubilant Organosys Ltd. Stabilized Sustained Release Composition of Bupropion Hydrochloride and Process For Preparing the Same
US20090246276A1 (en) * 2008-01-28 2009-10-01 Graham Jackson Pharmaceutical Compositions
FR2927331B1 (fr) * 2008-02-07 2011-05-20 Centre Nat Rech Scient Nouveaux derives anti-infectieux, leur procede de preparation, compositions pharmaceutiques les contenant et leurs utilisations en therapeutique.
EP2090297A1 (en) * 2008-02-13 2009-08-19 Boehringer Ingelheim International GmbH Formulations of flibanserin
JP5408131B2 (ja) * 2008-06-12 2014-02-05 住友ベークライト株式会社 半導体素子搭載基板
US8450376B2 (en) * 2008-06-16 2013-05-28 Glenmark Generics Ltd. Amorphous bupropion hydrobromide and preparation thereof
JP5506792B2 (ja) * 2008-06-25 2014-05-28 ブラーシュ・バイオテック・エルエルシー クロラムフェニコールアセチルトランスフェラーゼ（ｃａｔ）不完全ソマトスタチン融合タンパク質およびその使用
NZ590010A (en) * 2008-06-25 2013-01-25 Braasch Biotech Llc Compositions and methods treating growth hormone deficiency and/or an insulin-like growth factor 1 deficiency with somatostatin and an adjuvant
WO2010000783A1 (de) * 2008-07-02 2010-01-07 Basf Se Verfahren zum beschichten von tabletten
CA2934988A1 (en) 2008-08-07 2010-02-11 Valeant International Bermuda Bupropion hydrobromide polymorphs
AT507187B1 (de) 2008-10-23 2010-03-15 Helmut Dr Buchberger Inhalator
WO2010054308A1 (en) * 2008-11-10 2010-05-14 Med-El Elektromedizinische Geraete Gmbh Hydrogel-filled drug delivery reservoirs
FR2938431B1 (fr) 2008-11-14 2013-12-20 Debregeas Et Associes Pharma Nouvelle composition a base d'acide gamma-hydroxybutyrique
US8506936B2 (en) * 2008-11-25 2013-08-13 Watson Laboratories, Inc. Stabilized nicotine chewing gum
CA2686480A1 (en) 2008-12-15 2010-06-15 Boehringer Ingelheim International Gmbh New salts
US20100151021A1 (en) * 2008-12-16 2010-06-17 Venkatesh Gopi M Compositions Comprising Melperone
US20100160363A1 (en) * 2008-12-19 2010-06-24 Aaipharma Services Corp. Extended-release pharmaceutical formulations
US20100159001A1 (en) * 2008-12-19 2010-06-24 Cardinal John R Extended-Release Pharmaceutical Formulations
US20110081413A1 (en) * 2009-01-22 2011-04-07 Ashok Omray Pharmaceutical Compositions Comprising Phosphate-Binding Polymer
AU2010207740B2 (en) * 2009-01-26 2016-06-16 Nitec Pharma Ag Delayed-release glucocorticoid treatment of asthma
NZ582836A (en) * 2009-01-30 2011-06-30 Nitec Pharma Ag Delayed-release glucocorticoid treatment of rheumatoid arthritis by improving signs and symptoms, showing major or complete clinical response and by preventing from joint damage
DK3045043T3 (da) 2009-02-26 2020-08-03 Relmada Therapeutics Inc Orale farmaceutiske sammensætninger af 3-hydroxy-n-methylmorphinan med forlænget frigivelse og fremgangsmåde til anvendelse
ITMI20090384A1 (it) * 2009-03-13 2010-09-14 Dipharma Francis Srl Bupropione bromidrato amorfo e metodo per la sua preparazione
WO2010106555A2 (en) * 2009-03-17 2010-09-23 Shantilal, Doshi, Bimalkumar Directly compressible pre-granulated cellulose ether polymer and process for preparing the same
US20120045504A1 (en) * 2009-04-14 2012-02-23 Kathryn Whitehead oral drug devices and drug formulations
CN101811975B (zh) * 2009-04-20 2013-01-16 浙江普洛医药科技有限公司 氢溴酸安非他酮的多晶型物及其制备方法
GB2495563B (en) * 2009-04-28 2014-12-03 Isp Investments Inc Co-processed excipient compositions
JP2012528799A (ja) * 2009-06-02 2012-11-15 ダウ グローバル テクノロジーズ エルエルシー 徐放製剤
US8329208B2 (en) 2009-07-28 2012-12-11 Methylation Sciences International Srl Pharmacokinetics of S-adenosylmethionine formulations
US20110027342A1 (en) * 2009-07-28 2011-02-03 Msi Methylation Sciences, Inc. S-adenosylmethionine formulations with enhanced bioavailability
FR2949061B1 (fr) 2009-08-12 2013-04-19 Debregeas Et Associes Pharma Microgranules flottants
FR2949062B1 (fr) * 2009-08-12 2011-09-02 Debregeas Et Associes Pharma Nouvelles formulations pharmaceutiques contre le mesusage des medicaments
US8414950B2 (en) * 2009-10-15 2013-04-09 Purecircle Sdn Bhd High-purity rebaudioside D and low-calorie table top tablet containing the same
KR101783632B1 (ko) * 2009-11-06 2017-10-10 에스케이바이오팜 주식회사 주의력 결핍/과잉행동 장애(ａｄｈｄ)의 치료 방법
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
BR112012015084A2 (pt) * 2009-12-23 2017-03-07 Lupin Ltd composição farmacêutica de liberação lenta de iloperidone
HUE042593T2 (hu) * 2010-03-09 2019-07-29 Alkermes Pharma Ireland Ltd Alkoholnak ellenálló enterális gyógyszerkészítmények
ES2860676T3 (es) 2010-07-23 2021-10-05 Gruenenthal Gmbh Sales o cocristales de 3- (3-dimetilamino-1-etil-2-metil-propil) -fenol
PH12012502076A1 (en) * 2010-08-24 2013-02-04 Otsuka Pharma Co Ltd Suspension and cake composition containing carbostyryl derivative and silicone oil and/or silicone oil derivative
EP3485878A1 (en) * 2010-09-01 2019-05-22 Arena Pharmaceuticals, Inc. Modified-release dosage forms of 5-ht2c agonists useful for weight management
US9149959B2 (en) 2010-10-22 2015-10-06 Monosol Rx, Llc Manufacturing of small film strips
FR2967576B1 (fr) * 2010-11-18 2013-07-12 Advicenne Pharma Composition pharmaceutique comprenant du sel precurseur du cycle de krebs, en particulier du sel de citrate, et son utilisation comme medicament
JP5681819B2 (ja) 2011-02-11 2015-03-11 バットマーク・リミテッド 吸入器コンポーネント
CN102241597B (zh) * 2011-05-04 2014-01-08 浙江普洛家园药业有限公司 一种氢溴酸安非他酮晶型ⅰ的制备方法
WO2013043828A1 (en) * 2011-09-20 2013-03-28 Grain Processing Corporation Microspheres
US9481777B2 (en) 2012-03-30 2016-11-01 The Procter & Gamble Company Method of dewatering in a continuous high internal phase emulsion foam forming process
EP2949331A1 (en) 2012-10-17 2015-12-02 Methylation Sciences International SRL Compositions comprising s-adenosylmethionine and a gallic acid ester
US9989517B2 (en) 2013-06-27 2018-06-05 Ruprecht Keller Methods and compositions for marking urine samples to identify source
US9504656B2 (en) * 2013-10-21 2016-11-29 Banner Life Sciences, LLC Pharmaceutical compositions for poorly soluble active ingredients
US11478468B2 (en) 2013-11-05 2022-10-25 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US20160324807A1 (en) 2013-11-05 2016-11-10 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10512643B2 (en) 2013-11-05 2019-12-24 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US11590124B2 (en) 2013-11-05 2023-02-28 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11617728B2 (en) 2013-11-05 2023-04-04 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11129826B2 (en) 2013-11-05 2021-09-28 Axsome Therapeutics, Inc. Bupropion as a modulator of drug activity
US10772850B2 (en) 2013-11-05 2020-09-15 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11291638B2 (en) 2013-11-05 2022-04-05 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11382874B2 (en) 2013-11-05 2022-07-12 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10080727B2 (en) 2013-11-05 2018-09-25 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US11596627B2 (en) 2013-11-05 2023-03-07 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11344544B2 (en) 2013-11-05 2022-05-31 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10813924B2 (en) 2018-03-20 2020-10-27 Antecip Bioventures Ii Llc Bupropion and dextromethorphan for treating nicotine addiction
US11191739B2 (en) 2013-11-05 2021-12-07 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11141416B2 (en) 2013-11-05 2021-10-12 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11534414B2 (en) 2013-11-05 2022-12-27 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11617747B2 (en) 2013-11-05 2023-04-04 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11524007B2 (en) 2013-11-05 2022-12-13 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11285118B2 (en) 2013-11-05 2022-03-29 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11234946B2 (en) 2013-11-05 2022-02-01 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11510918B2 (en) 2013-11-05 2022-11-29 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11426401B2 (en) 2013-11-05 2022-08-30 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11357744B2 (en) 2013-11-05 2022-06-14 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11007189B2 (en) 2013-11-05 2021-05-18 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11090300B2 (en) 2013-11-05 2021-08-17 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US20160361305A1 (en) 2013-11-05 2016-12-15 Antecip Bioventures Ii Llc Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan
US10894046B2 (en) 2013-11-05 2021-01-19 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US9457025B2 (en) 2013-11-05 2016-10-04 Antecip Bioventures Ii Llc Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan
US12109178B2 (en) 2013-11-05 2024-10-08 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10874665B2 (en) 2013-11-05 2020-12-29 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US9861595B2 (en) 2013-11-05 2018-01-09 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US10966941B2 (en) 2013-11-05 2021-04-06 Antecip Bioventures Ii Llp Bupropion as a modulator of drug activity
US11576909B2 (en) 2013-11-05 2023-02-14 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10780064B2 (en) 2019-01-07 2020-09-22 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US9457023B1 (en) 2013-11-05 2016-10-04 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US10894047B2 (en) 2013-11-05 2021-01-19 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11576877B2 (en) 2013-11-05 2023-02-14 Antecip Bioventures Ii Llc Bupropion as modulator of drug activity
US9474731B1 (en) 2013-11-05 2016-10-25 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US9763932B2 (en) 2013-11-05 2017-09-19 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US11298352B2 (en) 2013-11-05 2022-04-12 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11058648B2 (en) 2013-11-05 2021-07-13 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US9700528B2 (en) 2013-11-05 2017-07-11 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US11364233B2 (en) 2013-11-05 2022-06-21 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11123343B2 (en) 2013-11-05 2021-09-21 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10874663B2 (en) 2013-11-05 2020-12-29 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10966942B2 (en) 2019-01-07 2021-04-06 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11541048B2 (en) 2013-11-05 2023-01-03 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11517543B2 (en) 2013-11-05 2022-12-06 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10874664B2 (en) 2013-11-05 2020-12-29 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11433067B2 (en) 2013-11-05 2022-09-06 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11571399B2 (en) 2013-11-05 2023-02-07 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10864209B2 (en) 2013-11-05 2020-12-15 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11439636B1 (en) 2013-11-05 2022-09-13 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10980800B2 (en) 2013-11-05 2021-04-20 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10799497B2 (en) 2013-11-05 2020-10-13 Antecip Bioventures Ii Llc Combination of dextromethorphan and bupropion for treating depression
US10786469B2 (en) 2013-11-05 2020-09-29 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US10940124B2 (en) 2019-01-07 2021-03-09 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11273134B2 (en) 2013-11-05 2022-03-15 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10105327B2 (en) 2013-11-05 2018-10-23 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphane and related pharmacodynamic effects
US10933034B2 (en) 2013-11-05 2021-03-02 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10881657B2 (en) 2013-11-05 2021-01-05 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11426370B2 (en) 2013-11-05 2022-08-30 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11291665B2 (en) 2013-11-05 2022-04-05 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11253491B2 (en) 2013-11-05 2022-02-22 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11298351B2 (en) 2013-11-05 2022-04-12 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11185515B2 (en) 2013-11-05 2021-11-30 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11497721B2 (en) 2013-11-05 2022-11-15 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11123344B2 (en) 2013-11-05 2021-09-21 Axsome Therapeutics, Inc. Bupropion as a modulator of drug activity
US10105361B2 (en) 2013-11-05 2018-10-23 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US11273133B2 (en) 2013-11-05 2022-03-15 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10945973B2 (en) 2013-11-05 2021-03-16 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US12194006B2 (en) 2013-11-05 2025-01-14 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US9707191B2 (en) 2013-11-05 2017-07-18 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US11541021B2 (en) 2013-11-05 2023-01-03 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11311534B2 (en) 2013-11-05 2022-04-26 Antecip Bio Ventures Ii Llc Bupropion as a modulator of drug activity
US11969421B2 (en) 2013-11-05 2024-04-30 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11147808B2 (en) 2013-11-05 2021-10-19 Antecip Bioventures Ii Llc Method of decreasing the fluctuation index of dextromethorphan
US9968568B2 (en) 2013-11-05 2018-05-15 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US9402843B2 (en) 2013-11-05 2016-08-02 Antecip Bioventures Ii Llc Compositions and methods of using threohydroxybupropion for therapeutic purposes
US11285146B2 (en) 2013-11-05 2022-03-29 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US9408815B2 (en) 2013-11-05 2016-08-09 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US20200338022A1 (en) 2019-01-07 2020-10-29 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11229640B2 (en) 2013-11-05 2022-01-25 Antecip Bioventures Ii Llc Combination of dextromethorphan and bupropion for treating depression
US11253492B2 (en) 2013-11-05 2022-02-22 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US20220233470A1 (en) 2013-11-05 2022-07-28 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10966974B2 (en) 2013-11-05 2021-04-06 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US9867819B2 (en) 2013-11-05 2018-01-16 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US11213521B2 (en) 2013-11-05 2022-01-04 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11020389B2 (en) 2013-11-05 2021-06-01 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11065248B2 (en) 2013-11-05 2021-07-20 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11096937B2 (en) 2013-11-05 2021-08-24 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10688066B2 (en) 2018-03-20 2020-06-23 Antecip Bioventures Ii Llc Bupropion and dextromethorphan for treating nicotine addiction
US11419867B2 (en) 2013-11-05 2022-08-23 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10898453B2 (en) 2013-11-05 2021-01-26 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11571417B2 (en) 2013-11-05 2023-02-07 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11207281B2 (en) 2013-11-05 2021-12-28 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11197839B2 (en) 2013-11-05 2021-12-14 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US9198905B2 (en) 2013-11-05 2015-12-01 Antecip Bioventures Ii Llc Compositions and methods for reducing dextrorphan plasma levels and related pharmacodynamic effects
EP3104842B1 (en) 2014-02-14 2021-10-06 Mission Pharmacal Company Sprayable composition containing zinc oxide and a fluoro-olefin propellant
MX375920B (es) * 2014-02-14 2025-03-07 Mission Pharma Co Emulsion estabilizada que puede rociarse que contiene particulas de agentes activos.
CN105980262B (zh) 2014-02-14 2020-08-04 明申医药公司 喷雾递送装置
MX383738B (es) * 2014-03-11 2025-03-14 Int N&H Usa Inc Composición y método de liberación prolongada.
US20150369794A1 (en) 2014-06-18 2015-12-24 Ruprecht Keller Method for Identifying of a Biological Sample of a Mammal, Composition for use in this method and Kit for Performance of this Method
CA2910865C (en) 2014-07-15 2016-11-29 Isa Odidi Compositions and methods for reducing overdose
US10441652B2 (en) 2014-08-21 2019-10-15 Braasch Biotech Llc Methods for improving immunological response in vaccinated animals
JP5941117B2 (ja) * 2014-10-17 2016-06-29 ダウ グローバル テクノロジーズ エルエルシー 徐放製剤
GB2535427A (en) 2014-11-07 2016-08-24 Nicoventures Holdings Ltd Solution
CA2978556C (en) * 2015-03-02 2022-02-15 Graphene 3D Lab Inc. Thermoplastic composites comprising water-soluble peo graft polymers useful for 3-dimensional additive manufacturing
JP6466792B2 (ja) * 2015-07-03 2019-02-06 エスケー バイオファーマスティカルズ カンパニー リミテッド 注意欠陥／多動性障害（ａｄｈｄ）の治療方法
GB2542838B (en) 2015-10-01 2022-01-12 Nicoventures Trading Ltd Aerosol provision system
US10543174B2 (en) * 2016-04-25 2020-01-28 Synthon B.V. Modified release tablet composition comprising mirabegron
US12433850B2 (en) 2016-05-05 2025-10-07 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine and prodrug compositions
JP7653218B2 (ja) 2016-05-05 2025-03-28 アクエスティブ セラピューティクス インコーポレイテッド 送達増強エピネフリン組成物
US12427121B2 (en) 2016-05-05 2025-09-30 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine compositions
US11273131B2 (en) 2016-05-05 2022-03-15 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
US12569479B2 (en) 2016-05-25 2026-03-10 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
WO2017222575A1 (en) 2016-06-23 2017-12-28 Collegium Pharmaceutical, Inc. Process of making more stable abuse-deterrent oral formulations
US10478399B2 (en) 2017-10-12 2019-11-19 Synthon B.V. Modified release tablet composition comprising mirabegron
WO2019087084A1 (en) 2017-11-02 2019-05-09 Eman Biodiscoveries Sd. Bhd. Extract of orthosiphon stamineus, formulations, and uses thereof
EP3846852A4 (en) * 2018-09-07 2022-06-15 R.P. Scherer Technologies, LLC Solid or semisolid lipid based dosage form stabilization through curing and addition of low hlb surfactant(s)
US11660274B2 (en) 2018-09-20 2023-05-30 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
US11660273B2 (en) 2018-09-20 2023-05-30 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
US11291639B2 (en) 2018-09-20 2022-04-05 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
US10925842B2 (en) 2019-01-07 2021-02-23 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
ES2952542T3 (es) 2019-07-04 2023-11-02 Ruma Gmbh Control de toma independiente de la ubicación
US12472156B2 (en) 2020-06-05 2025-11-18 Antecip Bioventures Ii Llc Compounds and combinations thereof for treating neurological and psychiatric conditions
US20250073188A1 (en) 2020-06-05 2025-03-06 Antecip Bioventures Ii Llc Compounds and combinations thereof for treating neurological and psychiatric conditions
US12433884B2 (en) 2020-06-05 2025-10-07 Antecip Bioventures Ii Llc Compounds and combinations thereof for treating neurological and psychiatric conditions
CN111830151B (zh) * 2020-07-01 2021-05-04 迪沙药业集团有限公司 盐酸安非他酮组合物质量控制用系统适用性对照品
BR112023001529A2 (pt) 2020-07-28 2023-04-11 Novelstar Pharmaceuticals Inc Nova forma de dosagem de liberação estendida gastroretentiva
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol
CN112646624A (zh) * 2020-11-30 2021-04-13 青岛科技大学 一种石墨烯复合水凝胶促进甲烷水合物高效生成的方法
CN116887866A (zh) 2020-12-03 2023-10-13 巴特尔纪念研究院 聚合物纳米颗粒和dna纳米结构组合物及用于非病毒递送的方法
JP2024516108A (ja) 2021-04-07 2024-04-12 バテル・メモリアル・インスティテュート 非ウイルス性担体を同定および使用するための迅速な設計、構築、試験、および学習技術
WO2022271167A1 (en) * 2021-06-23 2022-12-29 Elite Pharmaceutical Solution Inc. Oral dosage form of ticagrelor and preparation method thereof
US12465564B2 (en) 2021-10-25 2025-11-11 Aquestive Therapeutics, Inc. Oral and nasal compositions and methods of treatment
CN115096876B (zh) * 2022-06-20 2025-02-14 山东省分析测试中心 一种电致化学发光检测氟离子传感器及其应用方法
US11717518B1 (en) 2022-06-30 2023-08-08 Antecip Bioventures Ii Llc Bupropion dosage forms with reduced food and alcohol dosing effects
US11730706B1 (en) 2022-07-07 2023-08-22 Antecip Bioventures Ii Llc Treatment of depression in certain patient populations
EP4593814A1 (en) 2022-09-26 2025-08-06 Rose Research Center, LLC Combination for use in a method of preventing weight gain
EP4712796A2 (en) 2023-05-15 2026-03-25 Bonafide Health, LLC Sleep-improving compositions and methods of use
WO2025072751A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
US12083080B2 (en) * 2023-12-04 2024-09-10 Richard Louis Price Therapeutic methods using bupropion hydrobromide
US12441996B2 (en) 2023-12-08 2025-10-14 Battelle Memorial Institute Use of DNA origami nanostructures for molecular information based data storage systems
CN121972102A (zh) * 2024-10-30 2026-05-05 深圳华宝协同创新技术研究院有限公司 一种胶囊及其制备方法

Family Cites Families (220)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US459208A (en) 1891-09-08 Mechanical movement
US3117967A (en) 1962-04-02 1964-01-14 Smith Kline French Lab 2-biphenylyl-2-hydroxy-morpholinium halides
US4132753A (en) 1965-02-12 1979-01-02 American Cyanamid Company Process for preparing oral sustained release granules
US4344431A (en) 1969-03-24 1982-08-17 University Of Delaware Polymeric article for dispensing drugs
BE759838A (fr) 1969-12-04 1971-06-03 Wellcome Found Cetones a activite biologique
GB1340032A (en) 1969-12-04 1973-12-05 Wellcome Found Biologically active ketones
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3989586A (en) 1973-05-11 1976-11-02 The Dow Chemical Company Absorbent paper products and method of preparation
US4002173A (en) 1974-07-23 1977-01-11 International Paper Company Diester crosslinked polyglucan hydrogels and reticulated sponges thereof
US3992652A (en) 1974-09-09 1976-11-16 Gte Sylvania Incorporated Bulk electrical surge arrester
GB1478759A (en) 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4036788A (en) 1975-02-11 1977-07-19 Plastomedical Sciences, Inc. Anionic hydrogels based on heterocyclic N-vinyl monomers
US4021492A (en) 1975-03-24 1977-05-03 Sandoz, Inc. Dibromination process
US4034758A (en) 1975-09-08 1977-07-12 Alza Corporation Osmotic therapeutic system for administering medicament
US4077407A (en) 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4063064A (en) 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
SE414305B (sv) 1976-08-25 1980-07-21 Astra Laekemedel Ab Analogiforfarande for framstellning av eventuellt substituerade 2-amino-6-fenyl-5,5dimetyl 3-hexanon med antidepressiv aktivitet
EP0003002B1 (de) 1977-12-22 1984-06-13 Ciba-Geigy Ag Verwendung von aromatisch-aliphatischen Ketonen als Photoinitiatoren, photopolymerisierbare Systeme enthaltend solche Ketone und neue aromatisch-aliphatische Ketone
US4230687A (en) 1978-05-30 1980-10-28 Griffith Laboratories U.S.A., Inc. Encapsulation of active agents as microdispersions in homogeneous natural polymeric matrices
US4285987A (en) 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US4200098A (en) 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4235236A (en) 1979-02-12 1980-11-25 Alza Corporation Device for dispensing drug by combined diffusional and osmotic operations
CA1146866A (en) 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
US4347257A (en) 1979-10-09 1982-08-31 Burroughs Wellcome Co. Prolactin suppression in mammals
US4536518A (en) 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
US4346709A (en) 1980-11-10 1982-08-31 Alza Corporation Drug delivery devices comprising erodible polymer and erosion rate modifier
US4435449A (en) 1981-05-14 1984-03-06 Burroughs Wellcome Co. Treatment of minimal brain dysfunction (MBD)
US4425363A (en) 1981-05-14 1984-01-10 Burroughs Wellcome Co. Treatment of tardive dyskinesia in mammals
US4393078A (en) * 1982-03-15 1983-07-12 Burroughs Wellcome Co. Bupropion and ethanol
US4421736A (en) 1982-05-20 1983-12-20 Merrel Dow Pharmaceuticals Inc. Sustained release diethylpropion compositions
KR850001149A (ko) 1983-02-03 1985-03-16 마이클 피터 잭슨 2-3차-부틸아미노-3'-클로로프로피오페논 말레에이트의 제조방법
US4576604A (en) 1983-03-04 1986-03-18 Alza Corporation Osmotic system with instant drug availability
US4673405A (en) 1983-03-04 1987-06-16 Alza Corporation Osmotic system with instant drug availability
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
USRE33994E (en) 1983-08-16 1992-07-14 Burroughs Wellcome Co. Pharmaceutical delivery system
GB8322007D0 (en) 1983-08-16 1983-09-21 Wellcome Found Pharmaceutical delivery system
FR2553413B1 (fr) 1983-10-17 1986-03-21 Lafon Labor Derives de 4-alkyl-2-hydroxy-3-methyl-2-phenyl-morpholine, procede de preparation et utilisation en therapeutique
EP0147479A1 (en) 1983-12-23 1985-07-10 Merck & Co. Inc. A water and drug delivery system for suppository use
US4851228A (en) 1984-06-20 1989-07-25 Merck & Co., Inc. Multiparticulate controlled porosity osmotic
GB8417170D0 (en) 1984-07-05 1984-08-08 Wellcome Found Heterocyclic pharmaceutical compounds
US4629621A (en) 1984-07-23 1986-12-16 Zetachron, Inc. Erodible matrix for sustained release bioactive composition
US4507323A (en) 1984-07-25 1985-03-26 Burroughs Wellcome Co. Treatment of psychosexual dysfunctions
US4769027A (en) 1984-08-15 1988-09-06 Burroughs Wellcome Co. Delivery system
FR2569184A1 (fr) 1984-08-20 1986-02-21 Lafon Labor Derives de 1-(aminophenyl) therapeutique et leur procede de preparation
FR2569185B1 (fr) 1984-08-20 1986-09-05 Lafon Labor Derives de 1-(aminophenyl)-2-amino-ethanone, procede de preparation et utilisation en therapeutique
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4764378A (en) 1986-02-10 1988-08-16 Zetachron, Inc. Buccal drug dosage form
DE3612212A1 (de) 1986-04-11 1987-10-15 Basf Ag Verfahren zur herstellung von festen pharmazeutischen formen
GB8613689D0 (en) 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
ES2058111T3 (es) 1986-06-10 1994-11-01 Euro Celtique Sa Composicion de liberacion controlada de dihidrocodeina.
US4861598A (en) 1986-07-18 1989-08-29 Euroceltique, S.A. Controlled release bases for pharmaceuticals
US4970075A (en) 1986-07-18 1990-11-13 Euroceltique, S.A. Controlled release bases for pharmaceuticals
GB8626098D0 (en) 1986-10-31 1986-12-03 Euro Celtique Sa Controlled release hydromorphone composition
US4886668A (en) 1987-09-24 1989-12-12 Merck & Co., Inc. Multiparticulate controlled porosity osmotic pump
US4816263A (en) 1987-10-02 1989-03-28 Alza Corporation Dosage form for treating cardiovascular diseases comprising isradipine
US4959208A (en) 1987-10-19 1990-09-25 Ppg Industries, Inc. Active agent delivery device
JP2681373B2 (ja) 1988-07-18 1997-11-26 塩野義製薬株式会社 徐放性製剤の製造法
US5612059A (en) 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
DE3830353A1 (de) 1988-09-07 1990-03-15 Basf Ag Verfahren zur kontinuierlichen herstellung von festen pharmazeutischen formen
US5178868A (en) 1988-10-26 1993-01-12 Kabi Pharmacia Aktiebolaq Dosage form
US5202128A (en) 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
US5126145A (en) 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
EP0418596A3 (en) 1989-09-21 1991-10-23 American Cyanamid Company Controlled release pharmaceutical compositions from spherical granules in tabletted oral dosage unit form
US5071607A (en) 1990-01-31 1991-12-10 Alza Corporatino Method and apparatus for forming a hole in a drug dispensing device
IE65045B1 (en) 1990-04-28 1995-10-04 Takeda Chemical Industries Ltd Granulated preparations and method of producing the same
US5183690A (en) 1990-06-25 1993-02-02 The United States Of America, As Represented By The Secretary Of Agriculture Starch encapsulation of biologically active agents by a continuous process
DE4031881C2 (de) 1990-10-08 1994-02-24 Sanol Arznei Schwarz Gmbh Lösungsmittelfreie, oral zu verabreichende pharmazeutische Zubereitung mit verzögerter Wirkstoffreisetzung und Verfahren zu deren Herstellung
US5403593A (en) 1991-03-04 1995-04-04 Sandoz Ltd. Melt granulated compositions for preparing sustained release dosage forms
US5273758A (en) 1991-03-18 1993-12-28 Sandoz Ltd. Directly compressible polyethylene oxide vehicle for preparing therapeutic dosage forms
DE4138513A1 (de) 1991-11-23 1993-05-27 Basf Ag Feste pharmazeutische retardform
US5266331A (en) 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5681585A (en) 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5260068A (en) 1992-05-04 1993-11-09 Anda Sr Pharmaceuticals Inc. Multiparticulate pulsatile drug delivery system
US5350584A (en) 1992-06-26 1994-09-27 Merck & Co., Inc. Spheronization process using charged resins
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
JPH0657131A (ja) 1992-08-14 1994-03-01 Mitsubishi Petrochem Co Ltd 熱可塑性樹脂組成物
DE4227385A1 (de) 1992-08-19 1994-02-24 Kali Chemie Pharma Gmbh Pankreatinmikropellets
KR100225983B1 (ko) * 1992-10-26 1999-10-15 클라우스-디터 홈메리히, 디트리히 빌헬름 샤흐트 마이크로캡슐의 제조 방법
NZ260408A (en) 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
IT1265074B1 (it) 1993-05-18 1996-10-30 Istituto Biochimico Italiano Composizione farmaceutica a lento rilascio contenente come sostanza attiva un acido biliare
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5541231A (en) * 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
KR100354702B1 (ko) 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
US5891471A (en) 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
US5476528A (en) 1993-12-20 1995-12-19 Tennessee Valley Authority System for improving material release profiles
US5753712A (en) 1994-02-18 1998-05-19 Pinsker; Walter Treatment of migraine headaches and formulations
US5395626A (en) 1994-03-23 1995-03-07 Ortho Pharmaceutical Corporation Multilayered controlled release pharmaceutical dosage form
US5567439A (en) 1994-06-14 1996-10-22 Fuisz Technologies Ltd. Delivery of controlled-release systems(s)
US5698224A (en) 1994-06-27 1997-12-16 Alza Corporation Tacrine therapy
GB9417310D0 (en) 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents
US5683720A (en) 1994-10-28 1997-11-04 Fuisz Technologies Ltd. Liquiflash particles and method of making same
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US5945125A (en) 1995-02-28 1999-08-31 Temple University Controlled release tablet
US5698124A (en) 1995-05-18 1997-12-16 Lucent Technologies Inc. Magnesia fiber draw furnace
US5837284A (en) 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US5980945A (en) * 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
US6096339A (en) 1997-04-04 2000-08-01 Alza Corporation Dosage form, process of making and using same
US6271240B1 (en) * 1996-05-06 2001-08-07 David Lew Simon Methods for improved regulation of endogenous dopamine in prolonged treatment of opioid addicted individuals
US5919826A (en) 1996-10-24 1999-07-06 Algos Pharmaceutical Corporation Method of alleviating pain
GB9704064D0 (en) 1997-02-27 1997-04-16 Aromascan Plc Electronic circuits
PT996426E (pt) * 1997-06-05 2007-06-18 Bertex Pharma Gmbh Sistema multifásico
ES2248908T7 (es) 1997-06-06 2014-11-24 Depomed, Inc. Formas de dosificación de fármacos por vía oral y retención gástrica para liberación continuada de fármacos altamente solubles
US5963263A (en) 1997-06-10 1999-10-05 Winbond Electronic Corp. Method and apparatus requiring fewer number of look-up tables for converting luminance-chrominance color space signals to RGB color space signals
WO1999001111A1 (en) 1997-07-02 1999-01-14 Euro-Celtique, S.A. Stabilized sustained release tramadol formulations
PT1003476E (pt) 1997-08-11 2005-05-31 Alza Corp Forma de dosagem de agente activo de libertacao prolongada adaptada para retencao gastrica
ATE232384T1 (de) 1997-10-03 2003-02-15 Cary Medical Corp Zusammensetzungen zur behandlung von nikotinabhängigkeit, enthaltend mecamylamin und bupropion
US6652882B1 (en) * 1997-10-06 2003-11-25 Intellipharmaceutics Corp Controlled release formulation containing bupropion
US6066339A (en) 1997-10-17 2000-05-23 Elan Corporation, Plc Oral morphine multiparticulate formulation
US20060141036A1 (en) 1997-12-12 2006-06-29 Andrx Labs Llc HMG-CoA reductase inhibitor extended release formulation
US6221917B1 (en) * 1997-12-30 2001-04-24 American Home Products Corporation Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
US5968553A (en) 1997-12-30 1999-10-19 American Home Products Corporation Pharmaceutical composition containing bupropion hydrochloride and an inorganic acid stabilizer
AU2349999A (en) 1998-01-29 1999-08-16 Sepracor, Inc. Pharmacological uses of pure (+) -bupropion
JP2002501888A (ja) 1998-01-29 2002-01-22 セプラコア インコーポレーテッド 光学的に純粋な（−）−ビュープロピオンを用いて禁煙を支援するためのまたは疼痛や他の障害を治療するための方法および組成物
WO1999038502A1 (en) * 1998-01-29 1999-08-05 Sepracor Inc. Pharmaceutical uses of optically pure (+)-bupropion
WO1999038504A1 (en) 1998-01-29 1999-08-05 Sepracor Inc. Pharmaceutical uses of optically pure (-)-bupropion
US6365185B1 (en) 1998-03-26 2002-04-02 University Of Cincinnati Self-destructing, controlled release peroral drug delivery system
US6156342A (en) 1998-05-26 2000-12-05 Andex Pharmaceuticals, Inc. Controlled release oral dosage form
US6236697B1 (en) 1998-05-28 2001-05-22 Integrated Device Technology, Inc. Clock recovery for multiple frequency input data
US6150420A (en) 1998-06-01 2000-11-21 Theramax, Inc. Method for enhanced brain delivery of bupropion
US6153223A (en) 1998-06-05 2000-11-28 Watson Pharmaceuticals, Inc. Stabilized pharmaceutical compositions
US6033686A (en) * 1998-10-30 2000-03-07 Pharma Pass Llc Controlled release tablet of bupropion hydrochloride
US6096341A (en) 1998-10-30 2000-08-01 Pharma Pass Llc Delayed release tablet of bupropion hydrochloride
EP1652516A3 (en) * 1998-11-02 2006-05-17 ALZA Corporation Osmotic controlled delivery of active agents
CA2348871C (en) 1998-11-02 2009-04-14 John G. Devane Multiparticulate modified release composition
US6270805B1 (en) 1998-11-06 2001-08-07 Andrx Pharmaceuticals, Inc. Two pellet controlled release formulation for water soluble drugs which contains an alkaline metal stearate
JP4166955B2 (ja) 1998-12-08 2008-10-15 プラニスフィア コーポレイション ウイルス疾患を処置するためのビュープロピオン
US6238697B1 (en) 1998-12-21 2001-05-29 Pharmalogix, Inc. Methods and formulations for making bupropion hydrochloride tablets using direct compression
US6342249B1 (en) * 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
US6734213B2 (en) 1999-01-20 2004-05-11 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6706283B1 (en) 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
ES2238999T3 (es) * 1999-02-24 2005-09-16 University Of Cincinnati Uso de derivados de sulfamato para tratar trastornos en el control de los impulsos.
US8545880B2 (en) 1999-02-26 2013-10-01 Andrx Pharmaceuticals, Llc Controlled release oral dosage form
US20030035840A1 (en) * 2001-02-08 2003-02-20 Boyong Li Controlled release oral dosage form
US6589553B2 (en) 2001-02-08 2003-07-08 Andrx Pharmaceuticals, Inc. Controlled release oral dosage form
US6210716B1 (en) * 1999-02-26 2001-04-03 Andrx Pharmaceuticals, Inc. Controlled release bupropion formulation
US6342496B1 (en) 1999-03-01 2002-01-29 Sepracor Inc. Bupropion metabolites and methods of use
US6337328B1 (en) 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
US6280763B1 (en) * 1999-05-10 2001-08-28 Pierce Management, Llc Apparatus and method for transdermal delivery of bupropion
SE9902386D0 (sv) 1999-06-22 1999-06-22 Astra Ab New formulation
MXPA02002193A (es) 1999-08-31 2002-09-30 Gr Nenthal Gmbh Forma de administracion de accion retardada que contiene sacarinato de tramadol.
US6352721B1 (en) 2000-01-14 2002-03-05 Osmotica Corp. Combined diffusion/osmotic pumping drug delivery system
US6491949B2 (en) 2000-01-14 2002-12-10 Osmotica Corp. Osmotic device within an osmotic device
AR026148A1 (es) 2000-01-21 2003-01-29 Osmotica Argentina S A Dispositivo osmotico con pasaje preformado que aumenta de tamano
GB2357762B (en) 2000-03-13 2002-01-30 Lundbeck & Co As H Crystalline base of citalopram
UY26615A1 (es) 2000-03-16 2001-10-25 Pfizer Prod Inc Inhibidor de la glucogeno fosforilasa.
SE0001151D0 (sv) 2000-03-31 2000-03-31 Amarin Dev Ab Method for producing a controlled-release composition
US6306436B1 (en) 2000-04-28 2001-10-23 Teva Pharmaceuticals Usa, Inc. Stabilized, acid-free formulation for sustained release of bupropion hydrochloride
GB0012260D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition
AU2001280865A1 (en) * 2000-08-02 2002-02-13 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful for the treatment of depression
US6500457B1 (en) 2000-08-14 2002-12-31 Peirce Management, Llc Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
US7241804B1 (en) * 2000-08-18 2007-07-10 Fred Hutchinson Cancer Research Center Compositions and methods for modulating apoptosis in cells over-expressing Bcl-2 family member proteins
US6333332B1 (en) 2000-08-25 2001-12-25 Impax Laboratories, Inc. Stabilized pharmaceutical compositions containing bupropion hydrochloride
US6620439B1 (en) 2000-10-03 2003-09-16 Atul M. Mehta Chrono delivery formulations and method of use thereof
US6749867B2 (en) 2000-11-29 2004-06-15 Joseph R. Robinson Delivery system for omeprazole and its salts
US20050048126A1 (en) 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US20030072807A1 (en) 2000-12-22 2003-04-17 Wong Joseph Chung-Tak Solid particulate antifungal compositions for pharmaceutical use
US20020086054A1 (en) 2001-01-02 2002-07-04 Jiajiu Shaw Controlled release system that needs no drilling
US6780871B2 (en) * 2001-01-29 2004-08-24 Albany Medical College Methods and compositions for treating addiction disorders
US20030175349A1 (en) 2001-01-30 2003-09-18 Council Of Scientific And Industrial Research Pharmaceutical compostion for extended/sustained release of a therapeutically active ingredient
WO2002094323A1 (en) 2001-05-22 2002-11-28 Glaxo Group Limited Weight reduction or weight controlling composition
JP2005503425A (ja) 2001-05-24 2005-02-03 アレックザ モレキュラー デリヴァリー コーポレイション 所定の吸入ルートによる薬剤エステルの送出
US7766013B2 (en) 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
US6960357B2 (en) 2001-05-25 2005-11-01 Mistral Pharma Inc. Chemical delivery device
US6668449B2 (en) 2001-06-25 2003-12-30 Micron Technology, Inc. Method of making a semiconductor device having an opening in a solder mask
IN192057B (es) * 2001-07-19 2004-02-14 Ranbaxy Lab Ltd
US20030044462A1 (en) * 2001-08-20 2003-03-06 Kali Laboratories, Inc. Sustained release tablets containing bupropion hydrochloride
US6582737B2 (en) * 2001-09-25 2003-06-24 Peirce Management, Llc Pharmaceutical composition containing two active ingredients for smoking cessation
CA2447984A1 (en) * 2001-09-28 2003-04-03 Mcneil-Ppc, Inc. Dosage forms having an inner core and outer shell with different shapes
US7014868B2 (en) 2001-10-16 2006-03-21 Curators Of The University Of Missouri Hexameric complexes and their preparation
US20030185882A1 (en) * 2001-11-06 2003-10-02 Vergez Juan A. Pharmaceutical compositions containing oxybutynin
US8329217B2 (en) * 2001-11-06 2012-12-11 Osmotica Kereskedelmi Es Szolgaltato Kft Dual controlled release dosage form
EP1446396A1 (en) 2001-11-08 2004-08-18 Sepracor, Inc. Methods for treating depression and other cns disorders using enantiomerically enriched desmethyl- and didesmethyl-metabolites of citalopram
US20040102440A1 (en) * 2002-07-01 2004-05-27 Wong Erik Ho Fong Method of promoting smoking cessation
US20030158254A1 (en) * 2002-01-24 2003-08-21 Xenoport, Inc. Engineering absorption of therapeutic compounds via colonic transporters
PT1476138E (pt) 2002-02-21 2012-02-14 Valeant Internat Barbados Srl Formulações de libertação modificada de pelo menos uma forma de tramadol
EP1495034A2 (en) * 2002-04-10 2005-01-12 Esperion Therapeutics, Inc. Mimics of acyl coenzyme-a comprising pantolactone and pantothenic acid derivatives, compositions thereof, and methods of cholesterol management and related uses
IN192747B (es) * 2002-04-15 2004-05-15 Ranbaxy Lab Ltd
MXPA04011203A (es) * 2002-05-17 2005-07-14 Univ Duke Metodo para tratar la obesidad.
TW200414900A (es) 2002-06-28 2004-08-16
KR101228376B1 (ko) 2002-07-18 2013-01-31 사이토스 바이오테크놀로지 아게 합텐-캐리어 컨쥬게이트 및 그의 용도
GB0218811D0 (en) 2002-08-14 2002-09-18 Cenes Ltd Salts of morphine-6-glucuronide
US20040115263A1 (en) 2002-08-26 2004-06-17 Robertson David W. Use of bupropion for treating restless legs syndrome
JP2006503023A (ja) 2002-09-03 2006-01-26 バイオヴェイル ラボラトリーズ インコーポレイテッド スタチン薬物の放出調節ための医薬品製剤および方法
UA79011C2 (uk) * 2002-09-05 2007-05-10 Гвіда Енд К. С.П.А. Одноразовий самонагрівний або самоохолоджуваний контейнер, переважно для напоїв, та спосіб його виготовлення
WO2004024674A1 (en) 2002-09-10 2004-03-25 Eos Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ticaret A.S. Process for the preparation of bupropion hydrochloride
EP1567131A1 (en) * 2002-11-15 2005-08-31 Ranbaxy Laboratories, Ltd. Bupropion hydrochloride solid dosage forms
US6893660B2 (en) 2002-11-21 2005-05-17 Andrx Pharmaceuticals, Inc. Stable pharmaceutical compositions without a stabilizer
US9107804B2 (en) 2002-12-10 2015-08-18 Nortec Development Associates, Inc. Method of preparing biologically active formulations
CA2509043C (en) 2002-12-10 2013-08-13 Cps Orocel Llc Method of preparing biologically active formulations
EP1613333A1 (en) * 2003-04-04 2006-01-11 Pharmacia Corporation Oral extended release compressed tablets of multiparticulates
US20040254419A1 (en) * 2003-04-08 2004-12-16 Xingwu Wang Therapeutic assembly
ITMI20030762A1 (it) 2003-04-11 2004-10-12 Erregierre Spa Processo di cristallizzazione del bupropione cloridrato.
WO2004096201A1 (en) * 2003-04-29 2004-11-11 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
US8029822B2 (en) 2003-05-22 2011-10-04 Osmotica Kereskedelmi és Seolgáltató KFT Rupturing controlled release device having a preformed passageway
MXPA05012493A (es) * 2003-05-27 2006-05-25 Forest Laboratories Combinacion de un antagonista del receptor de nmda y un inhibidor selectivo de reabsorcion de serotonina para el tratamiento de depresion y otros trastornos de estado de animo.
IN2003MU00504A (es) 2003-06-05 2005-05-13 Alembic Ltd
US20050186276A1 (en) 2003-07-17 2005-08-25 Pfizer Inc Pharmaceutical formulations
US20050031688A1 (en) 2003-08-04 2005-02-10 Ayala William J. Positive wakeup pharmaceutical sleep system with compatible pre-bedtime administration
KR101087464B1 (ko) 2003-08-08 2011-11-25 밸리언트 인터내셔널(바베이도스) 에스알엘 부프로피온 히드로클로라이드의 개질 방출형 정제
WO2005060968A1 (en) * 2003-12-11 2005-07-07 Sepracor Inc. Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
US20050250838A1 (en) 2004-05-04 2005-11-10 Challapalli Prasad V Formulation for sustained delivery
WO2005115340A1 (en) 2004-05-19 2005-12-08 Glatt Air Techniques, Inc. Micropellet containing pellets and method of preparing such pellets
US20070212428A1 (en) * 2004-06-04 2007-09-13 Mood Management Sciences, Inc. Methods and compositions for treating mood disorder
CA2569411A1 (en) 2004-06-04 2005-12-22 Mood Management Sciences, Llc Methods and compositions for treating mood disorder
EP1791520A2 (en) 2004-08-19 2007-06-06 Alza Corporation Controlled release nanoparticle active agent formulation dosage forms and methods
US20060099262A1 (en) 2004-11-08 2006-05-11 Biokey, Inc. Methods and formulations for making controlled release oral dosage form
DE102004062475A1 (de) * 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
RU2408368C2 (ru) 2005-06-27 2011-01-10 Биовэйл Лэборэториз Интернэшнл С.Р.Л. Препараты соли бупропиона с модифицированным высвобождением
US7645802B2 (en) 2005-06-27 2010-01-12 Biovail Laboratories International Srl. Bupropion hydrobromide and therapeutic applications
US7671094B2 (en) 2005-06-27 2010-03-02 Biovail Laboratories International S.R.L. Bupropion hydrobromide and therapeutic applications
EP1954257A4 (en) * 2005-10-14 2009-05-20 Lundbeck & Co As H METHOD FOR TREATING DISORDERS OF THE CENTRAL NERVOUS SYSTEM WITH A LOW-DOSED COMBINATION OF ESCITALOPRAM AND BUPROPION
WO2007078895A2 (en) 2005-12-30 2007-07-12 Biovail Laboratories International S.R.L. Modified release formulations of tramadol and uses thereof
US7818264B2 (en) 2006-06-19 2010-10-19 Visa U.S.A. Inc. Track data encryption
US20090004281A1 (en) 2007-06-26 2009-01-01 Biovail Laboratories International S.R.L. Multiparticulate osmotic delivery system
CA2934988A1 (en) 2008-08-07 2010-02-11 Valeant International Bermuda Bupropion hydrobromide polymorphs

Also Published As

Publication number Publication date
US7585897B2 (en) 2009-09-08
RU2408368C2 (ru) 2011-01-10
US7569610B2 (en) 2009-08-04
AU2006261788A1 (en) 2007-01-04
US7645901B2 (en) 2010-01-12
US7884136B2 (en) 2011-02-08
US20100222435A1 (en) 2010-09-02
US8932628B2 (en) 2015-01-13
US20150202147A1 (en) 2015-07-23
US7553992B2 (en) 2009-06-30
US7662407B2 (en) 2010-02-16
KR101306635B1 (ko) 2013-10-11
US20070269516A1 (en) 2007-11-22
US7572935B2 (en) 2009-08-11
US20070281012A1 (en) 2007-12-06
US20080033044A1 (en) 2008-02-07
US7241805B2 (en) 2007-07-10
IL185760A0 (en) 2008-08-07
US20070276047A1 (en) 2007-11-29
JP2008546841A (ja) 2008-12-25
US20070293584A1 (en) 2007-12-20
EP1896002A2 (en) 2008-03-12
EP2502621A1 (en) 2012-09-26
US20080057120A1 (en) 2008-03-06
EP1896002A4 (en) 2009-11-25
AU2006261788B2 (en) 2012-05-31
WO2007002597A3 (en) 2009-04-23
US20070027213A1 (en) 2007-02-01
IL185760A (en) 2013-11-28
NZ561375A (en) 2011-06-30
US7579380B2 (en) 2009-08-25
US7649019B2 (en) 2010-01-19
KR20080026098A (ko) 2008-03-24
US20080038345A1 (en) 2008-02-14
ZA200711123B (en) 2009-08-26
CA2578626A1 (en) 2007-01-04
US20080051606A1 (en) 2008-02-28
US20080081068A1 (en) 2008-04-03
IL228989A0 (en) 2013-12-31
CA2578626C (en) 2011-07-19
US20080038348A1 (en) 2008-02-14
JP5095615B2 (ja) 2012-12-12
US20080033043A1 (en) 2008-02-07
CN101534808A (zh) 2009-09-16
US20080039441A1 (en) 2008-02-14
US7563823B2 (en) 2009-07-21
RU2007147343A (ru) 2009-08-10
US7569611B2 (en) 2009-08-04
ECSP077999A (es) 2008-01-23
WO2007002597A2 (en) 2007-01-04
US9504640B2 (en) 2016-11-29
EP2474308A1 (en) 2012-07-11

Similar Documents

Publication Publication Date Title
ECSP077999A (es) Formulaciones de una sal de bupropion de liberación modificada
SV2007002427A (es) Una formulacion solida de dosificacion farmaceutica
AR116052A2 (es) Forma cristalina de clorhidrato de (-)-(1r,2r)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenol
UY30438A1 (es) Derivados n-sustituidos de 5-halo-4-[2-alquil-1-sustituidos-1h-imidazol-5-il]pirimidin-2-amina, composiciones-procesos para su preparacion y usos
HN2003000417A (es) Intermedio de formulacion aceptablemente no higroscopico que comprende un farmaco higroscopico
MX2020008616A (es) Rocio de fentanilo sublingual.
CL2011000835A1 (es) Compuestos derivados de espiro-oxindol; moduladores de los canales de sodio; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento del dolor, depresion, enfermedades cardiovasculares, respiratorias, psiquiatricas, entre otras.
NO20043367L (no) Oralt farmasoytisk preparat
AR053162A1 (es) Compuesto 5 - oxo - pirrolidin sustituido, composicion farmaceutica que lo comprende y su uso para preparar un medicamento para el tratamiento del glaucoma.
ECSP088296A (es) Compuestos terapéuticos
CR9614A (es) Inhibidores heterobiciclicos de las metaloproteasas
UY30495A1 (es) Formulaciones de modificador de respuesta inmune
CU20080235A7 (es) Composiciones farmacéuticas estabilizadas que comprenden fesoterodina
UY30440A1 (es) Nuevos compuestos
CR9954A (es) Derivados de pirazina
UY30274A1 (es) Derivados sustituidos de la n-(4-metil-1,3-tiazol-2-il)guanidina, formulaciones farmacéuticas conteniéndolo y aplicaciones
BRPI0509184A (pt) composições farmacêuticas
NO20092535L (no) Fumaratsalt av (alfa S, beta R)-6-brom-alfa-[2-(dimetylamino)etyl]-2-metoksy-alfa-1-naftalenyl-beta-fenyl-3-kinolinetanol
ECSP088689A (es) NOVEDOSAS 11ß-HIDROXIANDROSTA-4-EN-3-ONAS
TNSN07293A1 (fr) Formes posologiques resistant a l'extraction alcoolique
DE602005027540D1 (de) Feste formulierungen von ospemifen
PE20150773A1 (es) Composiciones farmaceuticas para la liberacion sostenida de fenilefrina
BR122016006880B8 (pt) forma de dosagem contendo pantoprazol como ingrediente ativo
PA8623101A1 (es) Compuestos farmaceuticamente activos
PA8571901A1 (es) Nueva composicion farmaceutica